Skip to main content

$8 Billion Risperdal Verdict Slashed to $6.8 Million

$8 Billion Risperdal Verdict Slashed to $6.8 Million

$8 Billion Risperdal Verdict Slashed to $6.8 Million

Introduction

On Friday, Philadelphia Court of Common Pleas Judge Kenneth Powell drastically cut the $8 billion jury award passed October last to $ 6.8 million in punitive damages over Janssen Pharmaceuticals’ antipsychotic drug Risperdal, which caused a Maryland man to develop enlarged breasts.

The plaintiff was awarded $1.75 million as compensatory damages in 2015, which was later reduced to $685,000, against Janssen Pharmaceuticals, a Johnson & Johnson subsidiary.

Judge Powell denied Janssen’s post-trial motions in all other respects but brought the punitive damages award to 10 times the compensatory award of $680,000. In this two-sentence judgment, Judge Powell did not outline his reasoning for slashing the $8 billion jury award.

Thousands of lawsuits are filed against J&J, claiming that the powerful antipsychotic drug causes gynecomastia in boys, an undesired growth of breast tissue. Two coordinated actions are filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775, presided by Honorable William Highberger) and the other in Philadelphia (In Re: Risperdal Litigation, March 2010 Term, Case No. 100300296).

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.